NFKB1 and colitis: In addition to these compounds, Shuai Li et al. demonstrated that Gliclazide reduces colitis-associated colorectal cancer formation by decreasing colonic inflammation and regulating the AMPK-NF-κB signaling pathway, suggesting its potential as a preventive treatment for colitis-associated colorectal cancer [115].